Italfarmaco Enters Binding Term Sheet Agreement with Neupharma for an Exclusive Option to Develop and Commercialize Inhaled TeicoplaninBinding Term Sheet Agreement • August 1st, 2019
Fabio Borella, President and Co-founder of Neupharma added, “We believe Italfarmaco has the right resources and development expertise that will enable the inhaled formulation of teicoplanin to successfully enter the next stages of clinical development and ideally commercialization. On the whole we value the opportunity to collaborate with this well-established organization.”
Exhibit 6 BINDING TERM SHEET AGREEMENT This Binding Term Sheet Agreement ("Binding Term Sheet"), dated as of July 28, 2002, is entered into by and among, Genesis Health Ventures, Inc., a Pennsylvania corporation ("Parent"), NCS HealthCare, Inc., a...Binding Term Sheet Agreement • August 20th, 2002 • NCS Healthcare Inc • Retail-drug stores and proprietary stores • Ohio
Binding Term Sheet AgreementBinding Term Sheet Agreement • July 23rd, 2024 • Roadzen Inc. • Insurance agents, brokers & service
The Creditor named above agrees to extinguish all of the debt and/or liabilities associated with the above description in exchange for one of the following (check one):
